Mirum Pharmaceuticals Announces Primary Endpoint Met in Phase 3 EXPAND Study of LIVMARLI® (maralixibat) in Ultra-Rare Cholestatic Liver Diseases

Mirum Pharmaceuticals Announces Primary Endpoint Met in Phase 3 EXPAND Study of LIVMARLI® (maralixibat) in Ultra-Rare Cholestatic Liver Diseases ...

Mirum Pharmaceuticals' LIVMARLI Study Hits Key Endpoints in Rare Liver Diseases

Mirum Pharmaceuticals (NASDAQ:MIRM) said its Phase III EXPAND study of LIVMARLI, or maralixibat, met its primary endpoint and ...

Here's what to know if you're unsure about your measles immunity status

Vaccination is the best way to protect yourself against measles. For most adults, one shot of the MMR is considered enough protection. But there are certain situations that call for a second dose.
Syrian Arab News Agency

Idlib opens four health centers to serve returning families

Idlib Health Directorate opened four health centers on Monday in the towns of Kafr Amim, Sheikh Idris, Tal al-Touqan and Abu ...
BIOENGINEER

Children With Type 1 Diabetes Are Too Often Misdiagnosed, Major Review Finds

A scoping review of 27 studies finds that delayed diagnosis, missed recognition, and misclassification of paediatric type 1 ...
BioSpace

Celltrion to Present New Analyses of ZYMFENTRA® (infliximab-dyyb) in Crohn’s Disease and Ulcerative Colitis at ACG 2026

New data show favorable outcomes with subcutaneous infliximab following intravenous infliximab interruption, regardless of ...
Vietnam Investment Review on MSN

Celltrion presents Zymfentra clinical data at gastroenterology meeting

JERSEY CITY, N.J., Oct. 12, 2026 /PRNewswire/ -- Celltrion USA, Inc. today announced that two analyses evaluating ZYMFENTRA® (infliximab-dyyb) will be presented in oral presentations on Oct. 13 and 14 ...